Synthesis and structure of Ag(I), Pd(II), Rh(I), Ru(II) and Au(I) NHC-complexes with a pendant Lewis acidic boronic ester moiety

International audienceBifunctional Ag(I), Pd(II), Rh(I), Ru(II) and Au(I) complexes containing a NHC ligand and a pendant trivalent boron moiety have been synthesized in high yields. Fine-tuned reaction conditions were used to prevent potential ligand self-quenching or polymerization due to the eventual co-existence in situ of free NHC (Lewis base) and boronic ester (Lewis acid) in the same molecule

Slight variations around imidazole and boron chemistry : from catalysis to anion receptors

La conception et l’élaboration de nouveaux ligands en chimie organométallique évoluent vers le design de ligands multifonctionnels afin d’augmenter l'affinité ligand/métal/substrat et de mimer les catalyseurs de la nature comme les enzymes, en activant de manière synergique les différents partenaires de la réaction. Il existe dans la littérature très peu d’exemples de complexes organométalliques présentant une fonctionnalité acide de Lewis. Dans notre étude, nous avons opté pour l’utilisation d’un atome de bore trivalent pendant. Malgré la forte utilisation des dérivés du bore en catalyse acide de Lewis pour l’activation de divers électrophiles, la conception de tels ligands ambiphiles, pour des complexes organométalliques, a été peu décrite et la réactivité peu étudiée. Ce travail a donc pour but d’explorer et de valider la viabilité de leurs préparations et de leurs utilisations.La première partie de ces travaux a été consacrée au développement de nouveaux complexes bifonctionnels métal/NHC/ester boronique pendant de Pd(II), Rh(I), Ru(II), Au(I) et Cu(I) et leurs applications en catalyse, afin d’accéder à de nouveaux modes d’activation de petites molécules.Dans la deuxième partie, un nouveau mode d’activation efficace de la liaison B-H des carbènes boranes incorporant un bras allylique ou homoallylique par des complexes de rhodium pour accéder à une famille de NHC-boranes cycliques énantioenrichis a été développé.Enfin, la troisième partie constitue la synthèse des travaux sur deux nouvelles familles de cations boronium macrocycliques et leurs applications dans la reconnaissance des anions.Conception and elaboration of new ligands in organometallic chemistry evolved towards the design of multi-functional shape to increase the affinity ligand/metal/substrate to mimic nature’s catalysts, and to promote, in most cases, an increasing reactivity and selectivity in the catalytic process. Despite the significant development of N-heterocyclic carbene (NHC) ligands in organometallic chemistry since the last decade, complexes bearing pendant trivalent boron derivatives were so far overlooked.In this context, bifunctional ligands containing NHC and boron moieties have been developed and the corresponding Ag(I), Pd(II), Rh(I), Cu(I) and Ru(II) complexes were designed and prepared for a synergistic activation of both reaction partners by the metal center and the pendant Lewis acidic boron atom.During this work, B−H bond activation of NHC-boranes by a diphosphane-ligated cationic Rh complex was applied in an unprecedented intramolecular enantioselective hydroboration of simple olefins. This study led to a library of enantioenriched cyclic boranes in high yields (up to 94%) with high regio- (up to 100%) and enantioselectivities (er up to 99.2:0.8).As part of this work, new boronium macrocycles were synthesized in high yields and their anion binding ability was evaluated by fluorimetric and 1H NMR titration. These new macrocycles display high binding affinity for halides and oxoanions in the solid state, in solution and in the gas phase

Investigation of the rhodium-catalyzed hydroboration of NHC-boranes: the role of alkene coordination and the origin of enantioselectivity †

International audienceThe mechanism of the intramolecular enantioselective rhodium(I)-catalyzed hydroboration of NHC-boranes is investigated by experimental reactivity measurements and molecular electronic structure calculations , within the framework of the Density Functional Theory and the Random Phase Approximation methods. The crucial role of alkene coordination and the origin of enantioselectivity are discussed. Two possible mechanisms are considered, via either prior hydride migratory insertion or boron migratory insertion. The minimum energy computed pathway leads to the enantiomer experimentally observed, therefore supporting the hydride migratory insertion mechanism. Calculations of the final steps of the catalytic cycle, i.e. regeneration of the catalyst and release of the product, give us further insights into the mechanism and rationalize the experimental results

Philippe Picot de Lapeyrouse, Toulouse, [France], to James Edward Smith

'Flora Pyrenaica' ready for publication; asks Smith to assist in procuring subscribers

Straightforward and Controlled Shape Access to Efficient Macrocyclic Imidazolylboronium Anion Receptors

International audienceStraightforward synthesis of air- and waterstable bis-cationic macrocyclic imidazolylboronium anion receptors is described herein. By taking advantage of the bulky and rigid 9-borabicyclo[3.3.1]-nonane (9-BBN) attaching point and a well-designed bis-imidazolylaryl, highly stable dimeric imidazolylboronium macrocycles were synthesized. Additionally, NMR spectroscopy ( 1H, DOSY, and HOESY), mass spectrometry (MS), and X-ray diffraction studies revealed that these macrocyclic scaffolds can bind several monoanions with high association constants in DMSO, and are particularly sensitive for the MS detection of anions (with concentrations in the nm range). This anion/receptor interaction involves eight C-H binding sites, which include Csp2-H and unusual Csp3-H hydrogen-bonding donors

Hepatitis E Virus Seroprevalence and Associated Risk Factors in Pregnant Women Attending Antenatal Consultations in Senegal

In West Africa, research on the hepatitis E virus (HEV) is barely covered, despite the recorded outbreaks. The low level of access to safe water and adequate sanitation is still one of the main factors of HEV spread in developing countries. HEV infection induces acute or sub-clinical liver diseases with a mortality rate ranging from 0.5 to 4%. The mortality rate is more alarming (15 to 25%) among pregnant women, especially in the last trimester of pregnancy. Herein, we conducted a multicentric socio-demographic and seroepidemiological survey of HEV in Senegal among pregnant women. A consecutive and non-redundant recruitment of participants was carried out over the period of 5 months, from March to July 2021. A total of 1227 consenting participants attending antenatal clinics responded to a standard questionnaire. Plasma samples were collected and tested for anti-HEV IgM and IgG by using the WANTAI HEV-IgM and IgG ELISA assay. The overall HEV seroprevalence was 7.8% (n = 96), with 0.5% (n = 6) and 7.4% (n = 91) for HEV IgM and HEV IgG, respectively. One of the participant samples was IgM/IgG-positive, while four were declared indeterminate to anti-HEV IgM as per the manufacturer’s instructions. From one locality to another, the seroprevalence of HEV antibodies varied from 0 to 1% for HEV IgM and from 1.5 to 10.5% for HEV IgG. The data also showed that seroprevalence varied significantly by marital status (p < 0.0001), by the regularity of income (p = 0.0043), and by access to sanitation services (p = 0.0006). These data could serve as a basis to setup national prevention strategies focused on socio-cultural, environmental, and behavioral aspects for a better management of HEV infection in Senegal

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

Inhibition of Bruton’s tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S). Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist, and these patients have poor outcomes. To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degradation of both wild-type and C481S mutant BTK. We selected a lead PROTAC, MT-802, from several candidates on the basis of its potency to induce BTK knockdown. MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome. MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK. In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot. Collectively, these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

Inhibition of Bruton’s tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S). Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist, and these patients have poor outcomes. To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degradation of both wild-type and C481S mutant BTK. We selected a lead PROTAC, MT-802, from several candidates on the basis of its potency to induce BTK knockdown. MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome. MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK. In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot. Collectively, these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

Inhibition of Bruton’s tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S). Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist, and these patients have poor outcomes. To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degradation of both wild-type and C481S mutant BTK. We selected a lead PROTAC, MT-802, from several candidates on the basis of its potency to induce BTK knockdown. MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome. MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK. In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot. Collectively, these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL